A collaborative effort to evaluate treatment of liver and pancreatic tumors

HOUSTON, DENVER and CHICAGO ? The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences today announced a strategic research collaboration to evaluate the treatment of tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy. Under the agreement, MD Anderson and TriSalus […]

Read more